US Patent

US9919117 — Nozzles for nasal drug delivery

Method of Use · Assigned to Impel Neuropharma Inc · Expires 2033-03-17 · 7y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a nozzle design for delivering a mixture of aerosol propellant and drug formulation, specifically for intranasal use.

USPTO Abstract

A nozzle for use in delivering a mixture of aerosol propellant and drug formulation. The nozzle includes a drug product inlet configured to receive a mixture of aerosolized propellant and an intranasal dosage form. The inlet is disposed at the proximal end. A nozzle body is secured to the drug product inlet. Two or more channels are disposed within the body. Two or more orifice apertures are disposed at the distal end of the nozzle.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3218 — dihydroergotamine-mesylate

Patent Metadata

Patent number
US9919117
Jurisdiction
US
Classification
Method of Use
Expires
2033-03-17
Drug substance claim
No
Drug product claim
Yes
Assignee
Impel Neuropharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.